enGene Therapeutics Inc. - *W EXP 10/31/202 (ENGNW)

CUSIP: 29286M113

Q1 2024 13F Holders as of 31 Mar 2024

Security type / class
Equity / *W EXP 10/31/202
Total 13F shares
5,502,863
Total 13F value
$28,624,959
Share change
+806,840
SEC-reported price per share
$5.20
Number of holders
16
Value change
+$9,669,204
Number of buys
3
Number of sells
13

Security key

29286M113

Report period

Q1 2024

Institutions

16

Top holders

10

ENGNW full security history Ownership snapshot Full 13F holder table Newer quarter: Q2 2024 Previous quarter: Q4 2023 enGene Therapeutics Inc. SEC filings enGene Therapeutics Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of ENGNW - enGene Therapeutics Inc. - *W EXP 10/31/202 (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Vivo Capital, LLC
Disclosed value leader
FCPM III SERVICES B.V.
Comparable rows
6/15
Latest evidence
20 Feb 2024
13F 3/4/5 Lead comparable stake: 1% 9 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Vivo Capital, LLC leads the comparable SEC ownership view at 1%.

6 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Vivo Capital, LLC's linked filing trail.
Comparable ownership Top 5
Vivo Capital, LLC 1%
ROYAL BANK OF CANADA 0.06%
GOLDMAN SACHS GROUP INC 0.06%
CITADEL ADVISORS LLC 0.03%
UBS Group AG 0%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Vivo Capital, LLC
13F
Company
13F
1%
$6,264,447
678,705 shares
 — 31 Dec 2023
ROYAL BANK OF CANADA
13F
Company
13F
0.06%
$349,000
37,845 shares
 — 31 Dec 2023
GOLDMAN SACHS GROUP INC
13F
Company
13F
0.06%
$345,636
37,447 shares
 — 31 Dec 2023
CITADEL ADVISORS LLC
13F
Company
13F
0.03%
$185,126
20,057 shares
 — 31 Dec 2023
UBS Group AG
13F
Company
13F
0%
$17,879
1,937 shares
 — 31 Dec 2023
MORGAN STANLEY
13F
Company
13F
0%
$74
8 shares
 — 31 Dec 2023
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
16
Shares
5,502,863
Rows available
16
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2024 vs Q4 2023 Across Filers

Q4 2023 holders
21
Q1 2024 holders
16
Holder diff
-5
Investor Q4 2023 Shares Q1 2024 Shares Share Diff Share Chg % Q4 2023 value Q1 2024 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .